Skip to main content
. Author manuscript; available in PMC: 2021 Jun 11.
Published in final edited form as: J Med Chem. 2020 May 22;63(11):5865–5878. doi: 10.1021/acs.jmedchem.0c00168

Table 2.

Toxicity of VK analogs in HT-22-neurons.

Compounds No. Percentage of inhibition (%)a
50 μM 10 μM
3a 22.42 ± 6.63 10.78 ± 1.94
3b 16.97 ± 10.55 11.91 ± 2.21
3c 6.75 ± 1.29 3.81 ± 5.08
3d 17.78 ± 1.41 11.86 ± 9.27
3e 21.34 ± 3.42 28.77 ± 5.90
3f 15.01 ± 2.87 2.09 ± 1.41
3g 41.21 ± 2.98 14.81 ± 4.24
3h 38.26 ± 0.84 14.96 ± 2.48
3i 54.10 ± 6.32 16.83 ± 4.98
3j 56.37 ± 0.79 34.69 ± 5.28
3k 62.34 ± 0.07 33.70 ± 5.31
3l 36.29 ± 4.49 27.21 ± 0.82
3m 43.76 ± 2.83 35.37 ± 4.70
3n 2.09 ± 2.06 0.07 ± 0.03
3o 100.05 ± 0.21 83.84 ± 0.33
3p 100.96 ± 0.52 86.21 ± 0.26
3q 99.78 ± 0.16 82.63 ± 3.28
3r 96.69 ± 0.69 74.53 ± 0.62
3s 10.25 ± 6.61 11.53 ± 1.71
3t 64.21 ± 6.55 19.39 ± 9.48
3u 76.65 ± 3.41 25.66 ± 2.59
3v 69.02 ± 2.45 38.61 ± 0.01
3w 59.67 ± 0.11 25.52 ± 2.66
5a 17.54 ± 2.83 10.15 ± 1.34
5b 21.39 ± 3.72 11.24 ± 2.56
a

Note: Values are the mean ± SEM, three experiments were performed for each data (n = 3).

HHS Vulnerability Disclosure